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Abstract Biliary tract carcinoma is a rare malignancy with
multiple causes, which underlie the different genetic and mo-
lecular profiles. Cancer cell lines are affordable models,
reflecting the characteristics of the tumor of origin. They rep-
resent useful tools to identify molecular targets for treatment.
Here, we established and characterized from biological, mo-
lecular, and genetic point of view, an Italian intrahepatic chol-
angiocarcinoma cell line (ICC), the MT-CHC01. MT-CHC01
cells were isolated from a tumor-derived xenograft.
Immunophenotypical characterization was evaluated both at
early and after stabilization passages. In vitro biological, ge-
netic, and molecular features were also investigated. In vivo
tumorigenicity was assessed in NOD/SCID mice. MT-
CHC01cells retain epithelial cell markers, EPCAM, CK7,
and CK19, and some stemness and pluripotency markers,
i.e., SOX2, Nanog, CD49f/integrin-α6, CD24, PDX1,
FOXA2, and CD133. They grow as a monolayer, with a pop-
ulation double time of about 40 h; they show a low migration
and invasion potential. In low attachment conditions, they are
able to form spheres and to growth in anchorage-independent
manner. After subcutaneous injection, they retain in vivo tu-
morigenicity; the expression of biliary markers as CA19-9 and
CEAwere maintained from primary tumor. The karyotype is
highly complex, with a hypotriploid to hypertriploid modal
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number (3n+/−) (52 to 77 chromosomes); low level of HER2
gene amplification, TP53 deletion, gain of AURKAwere iden-
tified; K-RAS G12D mutation were maintained from primary
tumor toMT-CHC01 cells. We established the first ICC cell line
derived from an Italian patient. It will help to study either the
biology of this tumor or to test drugs both in vitro and in vivo.
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In vitro model
Introduction
Biliary tract carcinoma (BTC) is a malignant neoplasm de-
rived from cholangiocytes in different tracts of biliary tree.
Recent studies suggest that BTC could originate from a com-
bination of cholangiocytes, peribiliary gland around bile duct,
and progenitor of hepatocytes or hepatocytes. It can be classi-
fied into intrahepatic cholangiocarcinoma (ICC), originating
from the bile ducts within the liver, and extrahepatic cholan-
giocarcinoma (ECC) arising from bile duct outside the liver;
ECC can be further classified as perihilar and distal BTC [1].
Incidence and mortality rates from BTC, including ICC
(10 % of primary liver cancers in Western countries), are in-
creasing worldwide [2–5]. Patients with unresectable disease
(70–90 %) have a poor prognosis with a survival of less than
12 months following diagnosis. Conventional chemotherapy,
gemcitabine alone or in association with platinum derivatives,
and radiotherapy have not shown to be effective in improving
long-term survival [6, 7].
The lack of effective therapies against this tumor prompts
to investigate its molecular pathogenesis. Literature data ex-
tensively described risk factor promoting BTC; in particular,
the etiology is different according to geography and ethnicity:
infestation of the liver flukes, Opisthorchis viverrini, and
Clonorchis sinensis are common in Thailand, Vietnam and
Laos [8]; hepatolithiasis in Asian countries; and primary scle-
rosing cholangitis (PSC) in the Western countries [9]. Other
potential risk factors, which affect almost all the countries,
include cirrhosis, hepatitis B (HBV), hepatitis C viral
(HCV), and HIV infections, inflammatory bowel disease in-
dependent of PSC, alcohol, smoking, fatty liver disease, cho-
lelithiasis, and choledocholithiasis [10–12]. Altogether, these
factors contribute to the development of the BTC and they are
on the basis of genetic (gene mutations, chromosomal aberra-
tions) and molecular (transcriptional profiles, aberrant signal-
ing pathways) variability of these tumors [2].
To better characterize BTC, cancer cell lines represent an
important and indispensable tool. By 1980s, a number of BTC
cell lines, in particular originating from ECC, has been
established and reported in the literature, from Japanese, Ko-
rean, Thai, or Chinese patients [13–32]. Only a limited num-
ber of ICC cell lines has been described in literature. In
particular, to date, no human ICC cell line has been
established from a Western countries’ patient.
In this work, we describe a human Italian ICC cell line
obtained from a patient-derived xenograft (PDX) [33]. This
cell line could provide a new suitable model for preclinical
studies of molecular pathogenesis or drug efficacy.
Materials and methods
Establishment of ICC cell line from a PDX
The PDX was obtained from a tumor sample of a 60-year-old
Italian woman who underwent surgical resection for ICC. Bi-
ological material was obtained from patient who has signed
the informed consent, following institutional review board-
approved protocols (BPROFILING Protocol, no. 001-IRCC-
00 IIS-10^ approved by Comitato Etico Interaziendale of
A.O.U. San Luigi Gonzaga, Orbassano, Torino, Italy). This
institutional study provides molecular genetic analysis, set up
of primary cultures and the creation of PDX from tumor bio-
logical samples (primary tumor, metastasis, tumor cells taken
under paracentesis or thoracentesis procedures, and blood).
The tumor was histopathologically classified as pT2b pN0,
moderately differentiated (G2) intrahepatic bile duct carcino-
ma. Tumor sample was also evaluated for the presence of
HBV or HCV markers, resulting negative. The primitive tu-
mor was associated with chronic cholecystitis, but not associ-
ated with liver cirrhosis or chronic liver disease, primary scle-
rosing cholangitis, diabetes, obesity, alcohol consumption,
and tobacco smoking.
For PDX establishment, non-obese diabetic (NOD)/Shi-se-
vere combined immunodeficient (SCID) female mice (4–
6 weeks old) (Charles River Laboratory) were maintained
under sterile conditions in micro-isolator cages at the animal
facilities of the IRCCS-Candiolo. All animal procedures were
approved by the Institutional Ethical Committee for Animal
Experimentation (Fondazione Piemontese per la Ricerca sul
Cancro) and by the Italian Ministry of Health. Mice were
subcutaneously (s.c.) grafted with a fragment of 4×4 mm of
representative primary tumor. After 4 months, the primary
tumor was successfully engrafted in mice at first generation
and was named CHC001 PDX; after reaching a volume of
about 200 mm3, tumor was explanted and re-implanted in
new mice for a second generation. The stabilization was ob-
tained in fourth generation. To obtain the cell line, tumor
specimen derived from fourth generation of PDX, was enzy-
matically digested with collagenase (200 U/ml) (Sigma-Al-
drich, St. Louis, MO, USA) for 3 h at 37 °C. Collagenase
was inactivated by two washes in fetal bovine serum (FBS)
(all from Sigma-Aldrich, St. Louis, MO, USA). Single-cell
suspension was obtained by filtering the supernatant through
a 70-μm cell strainer (BD Biosciences, San Jose, CA). Cells
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were finally re-suspended in three different culture conditions:
complete DMEM, RPMI, and Knockout/DMEM/F-12 media
at a cell density of 300,000/mL in six-well tissue culture plates
at 37 °C in a humidified atmosphere of 95 % air and 5 % CO2.
Media were replaced twice a week. When cells reached 70–
80 % of confluence, they were propagated in the optimal cul-
ture condition (complete Knockout/DMEM/F-12 medium).
The stable cell line was named MT-CHC01.
Cell lines
The ICC cell line HuH28 (Cell Bank, RIKEN Bioresource
Center Riken Cell Bank, Japan) was cultured in RPMI 1640
containing 10% FBS (all from Sigma-Aldrich, St. Louis, MO,
USA), 100 U/mL penicillin and 100 μg/mL streptomycin (P/S
Life Technologies Gathersburg, MD). The extrahepatic chol-
angiocarcinoma (ECC) WITT cells (provided by Dr. Ander-
sen, BRIC Center, Copenhagen, Denmark) were cultured in
DMEM (Sigma-Aldrich) 10 % FBS. The authentication of all
the cell lines was performed by using Cell_ID system
(Promega) comparing their profile with those published on
the DMSZ database.
Flow cytometry analysis
The immunophenotype of MT-CHC01 cells was determined
by flow cytometric analysis. Cells were washed in 1× PBS
containing 0.1 % bovine serum albumin (BSA, Sigma-
Aldrich, Saint Louis, MO, USA) and 0.01 % sodium-azide.
For cell permeabilization, when requested, the Fix and Perm
reagent (BD Italia) was used following the manufacturer’s
instructions. The following antibodies were used: fluorescein
isothiocyanate (FITC)-conjugated mouse anti-CK7 and anti-
CK19 (Abcam Cambridge, UK) and CD44 (BD Bioscience
Europe), allophycocyanin (APC)-conjugated mouse mAbs
anti-EPCAM (BD), anti-CD34 and anti-CD133 (Miltenyi
BiotecS.r.l., Italy), phycoerytrin-conjugated (PE) anti-CD24,
anti-CXCR4, anti-Oct3/4, anti-FOXA1/2, anti-PDX1 (all
from BD), and anti-CD338 (R&D Systems, Inc. Minneapolis,
MN), PerCP-Cy 5.5-conjugated anti-SOX2/17, Alexafluor
647-conjugated anti-Nanog and anti-Stro1 (BD), and
Alexafluor 488-conjugated anti-PAX6 (BD).
Mycoplasma detection
The presence of mycoplasma DNAwas tested by the PCR kit
VenorGeM (Minerva Biolabs) following the manufacturer’s
instructions. The primers are specific to the highly conserved
16S rRNA coding region in the mycoplasma genome. Detec-
tion requires 1–5 fg of mycoplasma DNA.
Population doubling time
The population doubling time at passage 25was determined in
hemacytometer chamber by staining with trypan-blue dye.
Briefly, 1.4×105 cells were plated in 24-well plates in tripli-
cate in optimal medium. Viable cells were counted at 24, 48,
and 72 h after seeding. The average number of cells was cal-
culated in three different experiments.
To calculate the population doubling time (DT), we used
the following formula: DT=T ln2/ln(Xe/Xb), in which T is
the time duration of culture, Xe is the cell number at the end of
the incubation time and Xb is the cell number at the beginning
of the incubation time.
Anchorage-independent growth assay
Anchorage-independent growth was assessed by colony-
formation assay in soft agar culture. Briefly, 100,000 cells
were suspended in 0.5 ml 0.3 % (w/v) soft agar layered over
0.3 % (w/v) base agar in 24-well plates in quadruplicate. Com-
plete medium was added twice a week for the entire period of
incubation (3 weeks).
Sphere-formation assay
MT-CHC01 cells were seeded onto six-well plates (ultra-low
attachment surface) at 1.5×105 cells per well in stem cell
medium serum free (SC medium: DMEM-F12 medium, 1×
B27, 200 ng/mL human EGF, 10 ng/mL human FGF, 0.4 %
BSA, 4 μg/mL insulin and P/S). Sphere formation was mon-
itored on days 7, 10, and 14 after seeding.
In vitro motility
Motility was performed by wound-healing assay and by
8.0-μm transwell chambers (Costar, Cambridge, MA, USA).
For wound-healing assay, cells were seeded in triplicate in six-
well tissue culture plates and allowed to grow until 100 %
confluence. The cell layer was gently Bwounded.^ Cell migra-
tion toward the scraped area was observed in nine randomly
selected microscopic fields for each time point (up to 72 h).
Images were acquired with a Leica DM13000B Inverted Mi-
croscope (Leica). The gap distance was analyzed using
ImageJ software; 0 % represents the time of wound (T0).
Wound closure was calculated in three different experiments.
The percentage of closure was calculated as 100−(T/T0)×
100, where T represents the average wound closures at the
different time points. Statistical analysis was performed using
one-way ANOVA and multiple comparison test (GraphPad
software). The assay was performed in three different
experiments.
Motility was also performed by transwell chambers assay
(1 cm2/well, BD Falcon). The upper and lower cultures were
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separated by an 8-μm pore size poly-vinyl-pyrrolidone-free
polycarbonate filters (BD Falcon). The experiments were car-
ried out in triplicates.
After the incubation period, filters were fixed with metha-
nol and stained with 0.5 % crystal violet in 25 % methanol;
cells on the upper surface of the filters were removed using
cotton swabs. Cells invading the lower surface were counted
in five random fields and expressed as number of invading
cells per well.
Tumorigenicity in NOD/SCID Mice
MT-CHC01 cells at passage 35 were grown to 80 % conflu-
ence and trypsinized. For in vivo studies, NOD/Shi-SCID
female mice (4–6 weeks old) of about 20–25 g/each (Charles
River Laboratory) were maintained under sterile conditions in
micro-isolator cages at the animal facilities of the IRCCS-
Candiolo. All animal procedures were approved by the Insti-
tutional Ethical Committee for Animal Experimentation
(Fondazione Piemontese per la Ricerca sul Cancro) and by
the Italian Ministry of Health.
In three independent experiments, ten mice were subcuta-
neously (s.c.) injected into the right flank under anesthesia
(mixture of isoflurane and nitrous oxide) with 3.0×106 MT-
CHC01 cells in 50% growth factor-reduced BDMatrigel (BD
Biosciences, San Jose, CA). Tumor diameters were measured
weekly after cell injection up to tumor engraftment until
35 days after injection.
Immunohistochemistry
The expression of CA19-9, alpha fetoprotein (AFP), and
carcinoembryonic antigen (CEA) was evaluated. Tissues
derived from primary tumor, PDX, MT-CHC01 cell line,
and its xenograft were fixed in 10 % buffered formalin
and embedded in paraffin. The sections (4 μm thick)
were incubated in 0.01 mol/L citrate solution (pH 6)
for 5 min three times at intervals of 20 min; then, the
sections were soaked in 3 % H2O2 to block endogenous
peroxidase activity, followed by washing in PBS at pH
7.4. The sections were incubated with the primary anti-
bodies for AFP, CEA, CA19-9 (all from DAKO Corpo-
ration) for 30 min. Rabbit anti-human polyclonal anti-
body was used for AFP and CEA, and mouse anti-
human monoclonal antibody was used for CA19-9. Sub-
sequently, sections were incubated with biotinylated an-
tibody and peroxidase-labeled streptavidin. Staining was
completed after incubation with the freshly prepared
substrate–chromogen solution of 3,3′-diaminobenzidine
(DAB). Finally, sections were counterstained with Meyer’s
hematoxylin.
Chromosome analysis
Established cell line was subjected to chromosomal analysis
using G banding andMulti-Color FISH (M-FISH). Cells were
trypsinized using trypsin/EDTA after colcemid treatment
(10 μg/ml) for 1 to 3 h, and slides were prepared according
to standard methods. Briefly, cells were incubated in 0.075 M
KCl hypotonic solution for 20 min and fixed in methanol-
glacial acetic acid (3:1). G banding was performed using
2xSSC at 68 °C for 2 min and Wright’s stain for 2 min. Meta-
phase images were captured using an Olympus BX61 micro-
scope (Olympus Corporation, Tokyo, Japan) and analyzed by
CytoVision software (Leica Biosystems, Newcastle Ltd, UK).
An average banding resolution of 300 bands was achieved.
Aberrations were described according to the International Sys-
tem for Human Cytogenetic Nomenclature, 2013 [34].
M-FISH was performed with the aim of identifying com-
plex chromosomal rearrangements. The probe cocktail con-
taining 24 differentially labeled chromosome-specific paint-
ing probes (24xCyte kit MetaSystems, Altlussheim, Germa-
ny) was denatured and hybridized to denatured tumor meta-
phase chromosomes according to the manufacturer’s protocol
for the Human Multicolor FISH kit (MetaSystems). Briefly,
slides were incubated at 70 °C in saline solution (2xSSC),
denatured in NaOH, dehydrated in ethanol series, air-dried,
covered with 10 μl of probe cocktail (denatured) and hybrid-
ized for 2 days at 37 °C. The slides were then washed with
post-hybridization buffers, dehydrated in ethanol series, and
counter-stained with 10 μl of DAPI/antifade. The signal de-
tection and analysis of subsequent metaphases used the
Metafer system and Metasytems’ ISIS software (software for
spectral karyotypes).
Comparative genomic hybridization array
Genomic DNA from MT-CHC01 was extracted by Qiamp
DNA mini Kit (Qiagen), and high-resolution oligonucleotide
comparative genomic hybridization array (CGH) was per-
formed following standard operating procedures from Agilent
Technologies. One thousand nanograms of DNA were
digested by a double enzymatic digestion (AluIþRsa I),
fragmented, amplified, and purified. After the quantification
with NanoDrop, 2 μg of genomic DNA of both tumor
DNA and control DNA from Promega (Human Genomic
DNA Female N 30742202/male N 30993901) were la-
beled with CY5-dCTPs and CY3-dCTP, respectively,
and hybridized on glass array 2 X105 K at 65 °C for
40 h at 20 rpm. Slides were then washed and scanned on
an Agilent 4000C dual laser scanner, and images were
analyzed with Feature Extraction v10.5 software. Raw txt
files were then loaded into Cytogenomics software for
data processing and visualization.
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Fish analysis
FISH analysis was performed using the following probes:
ALK (2p23) Break Apart Rearrangement probe (Vysis,
Downers Grove, IL, USA), dual color AURKA (20q13)/
CEN20 probe (Kreatech Diagnostics, Amsterdam, Nether-
lands), dual color EGFR (7p12)/CEP7 probe (Vysis), dual
color HER2 (17q11.2)/CEP17 (DAKO, Glostrup, Denmark),
dual color MET (7q31.2)/CEP7 probe (Vysis) and dual color
TP53 (17p13.1)/CEP17 (Vysis) and Del(5q) Deletion probe
(Cytocell, Cambridge, UK). FISH was carried out on inter-
phase cells prepared according to standard techniques. Cells
were incubated with the probe for 5 min at 75 °C for co-
denaturation and placed in a humidified chamber at 37 °C
overnight for the hybridization step. After washing, chromatin
was counterstained with DAPI II (Vysis). An average of 100
cells was analyzed using a Olympus BX61 microscope and
CytoVision software. AURKA, EGFR,HER2,MET, and TP53
gene statuswas defined evaluating the ratio between the gene
copy number (CN) and the relative centromere number (ratio
CN/CEN) and the mean copy number of gene (ratio CN/nu-
clei). A gene amplification was defined when the ratio CN/
CEN was ≥2.0 and a gene/centromere gain when the mean
copy number was ≥3.
Mutational analysis
Genomic DNAwas extracted by using QIAamp DNA FFPE
Mini kit (Qiagen, Milan, Italy) following the manufacturer’s
instructions. The kinase domain of EGFR coding sequence,
from exons 18 to 21, was amplified by using primers and
nested polymerase chain reaction (PCR) conditions previous-
ly described by Lynch et al. [35]. Exon 2 of K-RAS, exons 9
and 20 of PI3KCA, and exon 15 of B-RAF were amplified by
PCR as previously described [36]. PCR products were then
purified using Wizard® SV Gel and PCR Clean-Up System
(Promega, Italy), and sense and antisense sequences were ob-
tained using forward and reverse internal primers respectively.
Each exon was sequenced using the BigDye Terminator Cycle
sequence following the PE Applied Biosystem strategy and
Applied Biosystem ABI PRISM3100 DNA Sequencer (Ap-
plied Biosystem, Forster City, CA). Mutations were con-
firmed performing two independent rounds of PCR
amplifications.
Results
Generation and immunophenotyping of ICC cell line
For the cell isolation, tumor tissue derived from the PDX at the
fourth generation was mechanically and enzymatically disso-
ciated. Cells adhered to the dish 24 h after plating, but only
1 week later, they formed scattered colonies. After 1 month in
the optimal cell culture conditions, Knockout/DMEM/F-12
medium in the presence of 10 % FBS and P/S, cells were
detached for the first time. At the 25th passage, after about
5 months, a stable cell line was obtained and named MT-
CHC01. It appears as a homogeneous culture of tumor cells
with epithelial morphologic features (Supplementary Fig. 1A
and B) and is mycoplasma free (Supplementary Fig. 1C).
Immunophenotypical analysis revealed that MT-CHC01
cell line expressed epithelial cell markers, such as EPCAM
(99.19 %), CK7 (98.99 %), and 19 (99.78 %) as shown in
Fig. 1 [14, 27].
The expression of different stemness and pluripotency
markers, already known to be typical of human biliary tree
[37] or others characteristics of other tumor types, was also
investigated. The establishedMT-CHC01 cells expressed high
levels of SOX2 (58 %), Nanog (96.3 %), CD49f/integrin α6
(98 %), CD24 (78 %), PDX1 (84.1 %), FOXA2 (94.2 %), and
CD133 (95.2 %) (Supplementary Table 1). Most of the same
markers, analyzed at early passages (Fig. 2a) were not
expressed; only CD133 and CD49f were at high levels, while
Nanog was expressed in about 30 % of the population versus
96.3 % of established MT-CHC01 cells (Fig. 2b). This sug-
gests that a phenotypic selection occurred in cultured
conditions.
Biological characterization of MT-CHC01 cell line
MT-CHC01 cells were able to grow in a monolayer in appro-
priate culture medium. After cell line stabilization, the popu-
lation doubling time was determined. In optimal culture con-
ditions, estimated as 1.4×105 cells/cm2, the population dou-
bling time was about 40 h (Supplementary Fig. 2).
Plating MT-CHC01 cells on soft agar medium for 3 weeks,
they were able to grow in an anchorage-independent manner
(Fig. 3a, b).
To confirm the stem cell status emerged from the expression
analysis of several stemness and pluripotencymarkers, a sphere-
formation assay was performed. As shown in Fig. 3c, d, MT-
CHC01 cells clearly formed spheres in low attachment and
serum-free conditions.
The MT-CHC01 motility was investigated by using both
wound healing and transwell chamber assays. Figure 4a–d
shows that the wound in MT-CHC01 cells was significantly
closed at 24, 48, and 72 h after the wound; the migration
potential of MT-CHC01 is lower if compared to other com-
mercial cell lines such as HuH28 (Fig. 4e), that closes the
wound within 24 h as previously demonstrated [38]. This data
was confirmed by transwell chamber assay (Fig. 4f–i), in
which we observed that MT-CHC01 cells had a lower migra-
tion potential rate (Fig. 4f) compared with the WITT (Fig. 4g)
and the HuH28 (Fig. 4h) cell lines.
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Tumorigenicity in vivo
To verify if the established cell line retained the tumorigenicity
in vivo, NOD/SCID mice were subcutaneously injected with
3.0×106 viable cells. In three independent experiments of ten
mice each, MT-CHC01 cells were able to develop tumor in all
animals. After 1–2 weeks, tumors reached a volume ranging
from 245 to 500 mm3; a cohort of mice (n=10) was monitored
for other 4 weeks when tumors reached volumes ranging from
1500 to 2100 mm3 (Supplementary Fig. 3); no evidence of
local invasion nor distant metastasis was revealed.
Hematoxylin/eosin staining and AFP, CA19-9, and CEA im-
munohistochemical analyses were also performed on primary
and PDX tumors, on MT-CHC01 cells, and on MT-CHC01
xenograft, revealing the same tissue architecture and patho-
logical phenotype of ICC [39] (Supplementary Fig. 4).
Genetic characterization of MT-CHC01 cell line
Mutational analysis
Mutational analysis of the kinase domain of EGFR coding
sequence (exons 18 to 21), exon 2 of K-RAS, exons 9 and
20 of PI3KCA, and exon 15 of B-RAF was performed in
primary tumor, and in MT-CHC01 cell line. As shown in
Fig. 5, only the sequence of K-RAS exon 2 was mutated
(G12D mutation) both in primary (Fig. 5b) and in MT-
CHC01 cells (Fig. 5c).
Conventional karyotyping and aCGH
To further genetically characterize MT-CHC01 cells, we per-
formed the chromosome G-banding analysis. The cytogenetic
Fig. 1 Immunophenotyping of
ICC cell line. Epithelial cell
markers are expressed in
established MT-CHC01 cells. a, b
Negative control: cells incubated
with antibody isotype as primary
antibody. Panels from C to E
represent FACS analysis of CK7
(98.99 %) (c), CK19 (98.78 %)
(d), and EPCAM (99.19 %) (e)
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analysis on ten metaphases of MT-CHC01 cells demonstrated
a highly complex karyotype with a hypotriploid to
hypertriploid modal number (3n+/−) (52 to 77 chromosomes).
Each chromosome harbored either numerical and/or structural
aberrations. M-FISH confirmed that the cell line was near-
triploid containing multiple chromosomal aberrations and
various marker chromosomes. The composite G-banded and
M-FISH karyotype (Fig. 6a, b, respectively), including all
clonal chromosomal aberrations observed in ten metaphases
o f MT-CHC01 ce l l s , was 52~77 < 3n > XXX, -1 ,
t (1;11)(q12;p12-14) ,der(2) t (2;5)(q31;q21) ,+3,-4,
d e r ( 4 ) t ( 2 ; 4 ) ( q 3 1 ; q 2 6 ) × 2 , - 6 , d e l ( 6 ) ( q 1 4 - 1 6 ) ,
Fig. 2 Expression of stemness and pluripotency markers in MT-CHC01 cell line at two different passages. Representative FACS analyses of SOX2/17,
PAX6, PDX1, Nanog, CD49f, and CD133 in early primary (a) and established (b) cell culture
Fig. 3 a, b Representative images of anchorage-independent growth of
MT-CHC01 cells in soft agar. Cells were suspended in 0.3 % soft agar
layered over 0.3 %. Medium was added twice a week for 3 weeks, and
colonies and cell aggregates were microscopically observed after
3 weeks. c, d Representative images of spheres obtained from MT-
CHC01 cells after 14 days of culture. Cells were seeded (ultra-low
attachment plate in stem cell medium (SC medium: DMEM-F12 medi-
um, 1× B27, 200 ng/mL human EGF, 10 ng/mL human FGF, 0.4 %
BSA, 4 μg/mL insulin and 100 U/mL penicillin/100 μg/mL streptomy-
cin). Sphere formation was monitored on days 7, 10, and 14 after
seeding. Bars correspond to 100 μm




d e r ( 1 6 ) t ( 1 ; 1 6 ) ( p 1 3 ; p 2 1 ) , + d e r ( 1 6 ) t ( 1 ; 1 6 )
( ? q 2 1 ; ? p 1 3 ) i n s ( 1 6 ; ? ) ( ? p 1 3 ; ? ) , - 1 7 , - 1 8 ,
der(22)t(16;22)(q10;?q10),+6mar[cp10]. Numerical and
structural alterations were present in all chromosomes, except
chromosomes 9 and 10. In particular, loss of chromosomes 4
and 6, gain of chromosome 16, der(4)t(2;4)(q31;q26),
der(8)t(5;8)(p13;p12) were present in all metaphases [10/10],




ins(16;?)(?p13;?) [6/10]. Chromosomes 1, 5, and 17 were
the most frequently involved. Supplementary Fig. 5 showed
the chromosome ideogram of a median of all structural aber-
rations observed in MT-CHC01 cell line. The complex karyo-
type of MT-CHC01 was further confirmed by comparative
genomic hybridization array (aCGH) (Supplementary Fig. 6).
FISH analysis on interphase nuclei
Interphase FISH was used to assess the status of ALK (2p23),
AURKA (20q13), EGFR (7p12), HER2 (17q11.2), MET
(7q31.2), and TP53 (17p13.1) genes with relation to the ob-
served chromosomal aberrations. ALK, EGFR, and MET
genes showed a trisomic pattern of signals reflecting the
near-triploid chromosomal assessment. As shown in Fig. 6c,
a low level of HER2 gene amplification (ratio CN/CEN, 2.1)
was observed, consistent with 17q instability and its involve-
ment in various rearrangements with multiple partner chromo-
somes. Moreover, a loss of TP53 was present if compared to
chromosome 17 centromere (TP53 mean copy number 2.2 vs
CEN17 mean copy number 3.1) as a consequence of 17p loss
detected in the karyotype.We observed a gain ofAURKA gene
(mean copy number 5.3) and chromosome 20 centromere
(mean copy number 4.1) not detectable in the karyotype, as
only three copies of chromosome 20 were always present.
Finally, to confirm the deletion on chromosome 5 detected
by CGH array, we performed a FISH analysis with a dual
Fig. 4 Migration ability of MT-CHC01 cells. a–dWound healing assay:
MT-CHC01 cells were seeded in six-well tissue culture plates and
allowed to grow until 100 % confluence. The cell layer was Bwounded^
and cell migration toward the scraped area was observed after the
wounding (a), 24 (b), 48 (c), and 72 h (d) in optimal culture conditions.
e Bars representing the area of closure at different time points; 100 %
corresponds to the area at the time of wounding. e–g Transwell migration
assay on MT-CHC01 (e), WITT (f), and HuH28 (g) cells. Cells were
seeded to the upper surface of a transwell chamber. The upper and lower
cultures were separated by a 8-μm pore size poly-vinyl-pyrrolidone-free
polycarbonate filters. i Bars represent the number of migrated cells. After
48 h of incubation period, filters were fixed with methanol and stained
with 0.5 % crystal violet in 25 % methanol and the cells on the upper
surface of the filters were removed using cotton swabs. Cells invading the
lower surface were counted in five random fields and expressed as num-
ber of invaded cells per well
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color probe specific for 5p15.31 and 5q31.2 regions. As ex-
pected, a loss of 5q31.2 regionwas detected if compared to the
copy number of 5p15.31 region (5p15.31 mean copy number
5 vs 5q31.2 mean copy number 4) (Fig. 6d).
Discussion
Biliary tract carcinoma is a complex and heterogeneous disease,
characterized by different incidence, etiology, genetic, and mo-
lecular profiles. In Italy, BTC shows progressive increase in
incidence mainly in intrahepatic cholangiocarcinoma [40].
The importance of identifying preclinical models able to
closely reflect the characteristics of tumor of origin is crucial.
To date, all models available have limits and consist of cell
lines derived from oriental patients. None of these models
derived from patient living in Europe and in particular in Italy.
In this work, we characterized a preclinical model repre-
sented by a cell line obtained from an Italian intrahepatic chol-
angiocarcinoma PDX.
The MT-CHC01 cell line was extensively characterized
from biological, molecular, and genetic point of view.
The MT-CHC01 cells grew as an adherent monolayer with
a population doubling time of approximately 40 h. The mor-
phology was clearly epithelial, and this status was confirmed
by immunophenotypic analysis, demonstrating that they
expressed epithelial cell markers, EPCAM, CK7, and CK19.
In soft agar medium, MT-CHC01 cells revealed the ability to
grow in anchorage-independent manner as cellular aggre-
gates; in low attachment and serum-free culture conditions
in stem cell medium, MT-CHC01 originated spheroid struc-
tures. A peculiar characteristic of cancer cells is their ability to
migrate; thus, we investigated the in vitro motility of the MT-
CHC01 cells. As demonstrated by wound healing and
transwell chamber assays, the MT-CHC01 cells showed a
low migration potential compared to other BTC cell lines,
reflecting the reduced metastatic potential of this tumor.
Immunophenotyping characterization demonstrated that
MT-CHC01 cells expressed, at high levels, some of stemness
and pluripotency markers such as SOX2, Nanog, CD49f,
CD24, PDX1, FOXA2, and CD133. Their expression was in-
creased during cell stabilization; at early passage of culture, the
other tested markers, with the exception of CD133, CD49f, and
Nanog, were scarcely represented. This could suggest that dur-
ing cell propagation, a clone selectionwith putative cancer stem
cell phenotype occurred, as demonstrated by Rowehl et al. in a
colorectal cancer cell line model [41]. The ability to grow in
suspension, to form spheres, to migrate, and to be tumorigenic
if s.c. injected in mice recipient, further supported this hypoth-
esis. Cancer stem cells represent a small population which sus-
tain tumor growth and have the capabilities of self-renewal and
multilineage differentiation; they also play an important role in
carcinogenesis and in resistance to therapies (chemotherapy
and target therapy) [42–44]. Our cell line, which has character-
istics of putative stem cells, could be an useful preclinical mod-
el to identify specific molecular targets of this subpopulation
and evaluate the effectiveness of combination therapies de-
signed to eradicate cancer stem cells and cancer.
It is known that tumor cells progressively acquired many
genetic and molecular alterations. Cytogenetic analysis of
MT-CHC01 cells confirmed a highly complex karyotype with
a hypotriploid to hypertriploid modal number (52 to 77 chro-
mosomes), multiple chromosomal aberrations, and various
marker chromosomes. With the exception of chromosomes 9
and 10, numerical and structural alterations were observed, in
Fig. 5 Electropherograms of K-RAS (exon 2). Wild-type sequence of K-
RAS exon 2 in WITT cells (a), and K-RAS G12D mutation found in
primary tumor (b) and in MT-CHC01 cell line (c)
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particular in chromosomes 1, 4 (loss), 5, 6 (loss), 16 (gain),
and 17 (loss). Only few data are available in literature on
cytogenetic of BTC, but most of them, derived from BTC cell
lines karyotyping, showed chromosomal aberration in chro-
mosomes 2, 4, 5, 7, 8, 9, 13, 17, 18, 19, X, and Y [13, 26, 28,
45, 46]. The complex karyotype of MT-CHC01 was further
confirmed by aCGH analysis; it revealed a huge number of
chromosomic aberrations; in particular, there is the gain of
chr 2q, 3q, 12p, and the loss of 3p, 5q, 6p, 8p, 9p, 18q, already
described in BTC by Rijken and collaborators [45, 47].
Further, genetic characterization was focused on mutation-
al status of the hotspot of EGFR (from exons 18 to 21) and its
principle signal transducers (exon 2 of K-RAS, exons 9 and 20
of PI3KCA, exon 15 of B-RAF); only a mutation of KRAS
(G12D) was found. Other genomic analyses revealed loss of
TP53, ALK, EGFR, andMET genes showed a trisomic pattern
of signals, low level ofHER2 gene amplification, and a gain of
AURKA gene.
In conclusion, we established a human intrahepatic cholan-
giocarcinoma cell line, derived from an Italian patient, which
could represent a useful tool to better characterize this disease
in relation to etiology and ethnicity and to develop new ther-
apies for ICC patients.
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Fig. 6 Genetic characterization of MT-CHC01 cells. Representative G-
banded karyotype (a) and M-FISH karyogram (b) of the MT-CHC01 cell
line. Note the presence of many marker chromosomes (mar). c. FISH
analysis of ALK (red/green fusion signal); AURKA, EGFR, HER2,
MET, and TP53 genes (red signals) and relative centromeres (green sig-
nals). The white arrow shows the TP53 loss on metaphase. d. FISH
analysis with a dual color probe specific for 5p15.31 and 5q31.2
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